Published in Healthcare Mergers, Acquisitions and Ventures Week, June 30th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at ThromboGenics.
Report 1: ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on vascular disease, today provided an update highlighting progress with its pre-clinical development portfolio. As part of this update, the Company announced an out-licensing agreement for the antibodies against platelet glycoprotein Ib (anti-GPIb) and von Willebrand Factor (anti-vWF), which it has been developing as novel anti-thrombotic agents. This out-licensing deal has been concluded so that the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.